Renal Cell Carcinoma Specialty Channel

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology

News

Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence

04/25/2024

Stephanie Holland

According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...

According to interim analysis...

04/25/2024

Oncology

News

Pazopanib Failed to Improve Long-Term Survival Results Among Patients With Metastatic Renal Cell Carcinoma Post-Metastasectomy at High Risk of Recurrence

04/16/2024

Stephanie Holland

According to results from the ECOG-ACRIN E2810 study, pazopanib did not improve long-term disease-free survival or overall survival among patients with metastatic renal cell carcinoma with no evidence of disease after metastasectomy at high...

According to results from the...

04/16/2024

Oncology

Quiz

Belzutifan vs Everolimus for Quality of Life of Patients With Advanced Clear Cell Renal Cell Carcinoma

03/21/2024

Did belzutifan improve the time to deterioration among patients with advanced clear cell renal cell carcinoma when compared with everolimus?

Did belzutifan improve the time...

03/21/2024

Oncology

News

Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma

03/11/2024

Allison Casey

A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.

A recent study found the use of...

03/11/2024

Oncology

News

Cabozantinib Dose Reductions May Indicate Adequate Dose Exposure Among Patients With Metastatic Renal Cell Carcinoma

03/11/2024

Allison Casey

According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.

According to a retrospective...

03/11/2024

Oncology

Conference Coverage

Belzutifan Improves Quality of Life Among Patients With Advanced Clear Cell Renal Cell Carcinoma

01/27/2024

Featuring Thomas Powles, MBBS, MD

Featuring Thomas Powles, MBBS, MD ...

Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.

Thomas Powles, MBBS, MD,...

01/27/2024

Oncology

Conference Coverage

Adjuvant Pembrolizumab Succeeds For Patients With Renal Cell Carcinoma At Increased Risk of Relapse

01/27/2024

Allison Casey

Adjuvant pembrolizumab significantly improved overall survival among patients with renal cell carcinoma at an increased risk for recurrence after surgery, when compared with placebo.

Adjuvant pembrolizumab...

01/27/2024

Oncology

Conference Coverage

Adjuvant Nivolumab Failed to Meet End Point for Patients With Renal Cell Carcinoma

01/27/2024

Allison Casey

In Part B of CheckMate 914, adjuvant nivolumab monotherapy failed to meet the primary end point of disease-free survival for patients with renal cell carcinoma at high risk of relapse following nephrectomy.

In Part B of CheckMate 914,...

01/27/2024

Oncology

Conference Coverage

Subcutaneous Nivolumab Noninferior to Intravenous Administration Among Patients With Clear Cell Renal Cell Carcinoma

01/27/2024

Featuring Saby George, MD

Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.

Saby George shares insights from...

01/27/2024

Oncology

News

Belzutifan Plus Cabozantinib Shows Promise in Previously Treated Clear Cell Renal Cell Carcinoma

04/12/2023

In a phase 2 trial, belzutifan plus cabozantinib showed promising antitumor activity among patients with clear cell renal cell carcinoma who had received prior PD-1/PD-L1 inhibition.

In a phase 2 trial, belzutifan...

04/12/2023

Oncology

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology

News

Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence

04/25/2024

Stephanie Holland

According to interim analysis...

04/25/2024

Oncology

News

Pazopanib Failed to Improve Long-Term Survival Results Among Patients With Metastatic Renal Cell Carcinoma Post-Metastasectomy at High Risk of Recurrence

04/16/2024

Stephanie Holland

According to results from the...

04/16/2024

Oncology

News

Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma

03/11/2024

Allison Casey

A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.

A recent study found the use of...

03/11/2024

Oncology

News

Cabozantinib Dose Reductions May Indicate Adequate Dose Exposure Among Patients With Metastatic Renal Cell Carcinoma

03/11/2024

Allison Casey

According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.

According to a retrospective...

03/11/2024

Oncology

Conference Coverage

Belzutifan Improves Quality of Life Among Patients With Advanced Clear Cell Renal Cell Carcinoma

01/27/2024

Featuring Thomas Powles, MBBS, MD

Featuring Thomas Powles, MBBS, MD ...

Thomas Powles, MBBS, MD,...

01/27/2024

Oncology

Conference Coverage

Adjuvant Pembrolizumab Succeeds For Patients With Renal Cell Carcinoma At Increased Risk of Relapse

01/27/2024

Allison Casey

Adjuvant pembrolizumab significantly improved overall survival among patients with renal cell carcinoma at an increased risk for recurrence after surgery, when compared with placebo.

Adjuvant pembrolizumab...

01/27/2024

Oncology

Conference Coverage

Adjuvant Nivolumab Failed to Meet End Point for Patients With Renal Cell Carcinoma

01/27/2024

Allison Casey

In Part B of CheckMate 914,...

01/27/2024

Oncology

Conference Coverage

Subcutaneous Nivolumab Noninferior to Intravenous Administration Among Patients With Clear Cell Renal Cell Carcinoma

01/27/2024

Featuring Saby George, MD

Saby George shares insights from...

01/27/2024

Oncology

News

Belzutifan Plus Cabozantinib Shows Promise in Previously Treated Clear Cell Renal Cell Carcinoma

04/12/2023

In a phase 2 trial, belzutifan plus cabozantinib showed promising antitumor activity among patients with clear cell renal cell carcinoma who had received prior PD-1/PD-L1 inhibition.

In a phase 2 trial, belzutifan...

04/12/2023

Oncology

Interactive Features

Quiz

Belzutifan vs Everolimus for Quality of Life of Patients With Advanced Clear Cell Renal Cell Carcinoma

03/21/2024

Did belzutifan improve the time to deterioration among patients with advanced clear cell renal cell carcinoma when compared with everolimus?

Did belzutifan improve the time...

03/21/2024

Oncology

Quiz

Quiz: Post-Surgery Everolimus for High-Risk Renal Cell Carcinoma

09/02/2022

In the phase 3 EVEREST trial which looked at everolimus after surgery in patients with high-risk renal cancer, which patients saw the greatest benefit in recurrence-free survival with everolimus?

In the phase 3 EVEREST trial...

09/02/2022

Oncology

Test Your Knowledge

Quiz: Which Study Yields Notable Benefit in Kidney Cancer?

04/15/2021

Which study reported OS results in favor of axitinib plus pembrolizumab, ultimately obtaining the lowest hazard ratio observed for survival in any phase 3 trial, a benefit seen across prognostic risk groups and regardless of PD‑L1 expression...

Which study reported OS results...

04/15/2021

Oncology

Test Your Knowledge

Quiz: Which Combo Regimen Received FDA Approval for Treatment of Advanced RCC?

02/02/2021

Which combo therapy regimen was approved by the FDA for the treatment of advanced RCC in January 2021?

Which combo therapy regimen was...

02/02/2021

Oncology

Test Your Knowledge

Quiz: Which Therapy Had Higher Safety, OS in Papillary RCC?

10/13/2020

Which therapy had a better safety profile and OS rate in the SAVOIR trial for papillary RCC?

Which therapy had a better...

10/13/2020

Oncology

Test Your Knowledge

Quiz: Is Pembrolizumab Plus Bevacizumab Beneficial for Metastatic RCC?

09/02/2020

True or False: Pembrolizumab combined with bevacizumab was proven safe and active in a study of patients with metastatic clear cell renal cell carcinoma.

True or False: Pembrolizumab...

09/02/2020

Oncology

Test Your Knowledge

Quiz: Is Ipilimumab Plus Nivolumab Active in Patients with Metastatic RCC?

07/31/2020

True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.

True or false: Ipilimumab plus...

07/31/2020

Oncology

Test Your Knowledge

Quiz: Does Nivolumab–Ipilimumab Yield Long-Term Benefit in Advanced RCC?

10/01/2019

True or False: Combining nivolumab therapy with ipilimumab has shown long-term benefit in advanced RCC.

True or False: Combining...

10/01/2019

Oncology

Recent News

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology

News

Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence

04/25/2024

Stephanie Holland

According to interim analysis...

04/25/2024

Oncology

News

Pazopanib Failed to Improve Long-Term Survival Results Among Patients With Metastatic Renal Cell Carcinoma Post-Metastasectomy at High Risk of Recurrence

04/16/2024

Stephanie Holland

According to results from the...

04/16/2024

Oncology

News

Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma

03/11/2024

Allison Casey

A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.

A recent study found the use of...

03/11/2024

Oncology

News

Cabozantinib Dose Reductions May Indicate Adequate Dose Exposure Among Patients With Metastatic Renal Cell Carcinoma

03/11/2024

Allison Casey

According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.

According to a retrospective...

03/11/2024

Oncology

News

Belzutifan Plus Cabozantinib Shows Promise in Previously Treated Clear Cell Renal Cell Carcinoma

04/12/2023

In a phase 2 trial, belzutifan plus cabozantinib showed promising antitumor activity among patients with clear cell renal cell carcinoma who had received prior PD-1/PD-L1 inhibition.

In a phase 2 trial, belzutifan...

04/12/2023

Oncology

News

Bevacizumab Plus Sunitinib for Patients With Advanced Renal Cell Carcinoma

01/26/2023

Allison Casey

In a phase 1/2 study, the addition of bevacizumab to a sunitinib on/off regimen demonstrated anti-tumor activity for patients with advanced renal cell carcinoma.

In a phase 1/2 study, the...

01/26/2023

Oncology

News

Nivolumab, Ipilimumab, and Cabozantinib Triplet Therapy Demonstrates Clinical Activity for Patients With Advanced Renal Cell Carcinoma

12/01/2022

Allison Casey

According to results from a discontinued arm of a phase 3 trial, the immunotherapy triplet regimen of nivolumab, ipilimumab, and cabozantinib demonstrated clinical activity in previously untreated patients with advanced renal cell carcinoma.

According to results from a...

12/01/2022

Oncology

News

Frontline Axitinib Plus Pembrolizumab vs Ipilimumab Plus Nivolumab for Metastatic Renal Cell Carcinoma

10/31/2022

Findings from a comparative effectiveness analysis show no statistically significant difference in survival outcomes between axitinib plus pembrolizumab vs ipilimumab plus nivolumab for the frontline treatment of patients with metastatic...

Findings from a comparative...

10/31/2022

Oncology

News

Sapanisertib With or Without TAK-117 vs Everolimus for Clear Cell Renal Cell Carcinoma

10/27/2022

In a phase 2 study, sapanisertib with or without TAK-177 demonstrated lower tolerability with no improvement in efficacy vs everolimus for patients with advanced clear cell renal cell carcinoma.

In a phase 2 study, sapanisertib...

10/27/2022

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology